Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Double-blind, Parallel, Placebo-Controlled, Phase III Clinical Trial to Evaluate Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients

NCT05084911 is registered in ClinicalTrials.gov with Shin Poong Pharmaceutical Co. Ltd. as lead sponsor.

NCT NCT05084911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05084911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Double-blind, Parallel, Placebo-Controlled, Phase III Clinical Trial to Evaluate Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients
Lead sponsor
Shin Poong Pharmaceutical Co. Ltd.
Phase
Phase 3
Overall status
Completed
Start date
October 18, 2021
Completion date
March 24, 2023
Enrollment
1,807 (actual)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19